| Name | Title | Contact Details |
|---|
At bluebird bio, we`re pioneering the uniquely promising world of gene therapy with a deep sense of purpose – to ensure lives are lived fully. To do it, we`re developing one-time gene therapies for severe genetic disease and cancer, while working to radically improve healthcare systems so gene therapy becomes truly accessible. We want to recode science, systems and the status quo – for life. We pride ourselves on having a unique culture that drives our success. A diverse flock of individual birds, we share common DNA that helps us build meaningful relationships with industry, patient & advocacy groups and our customers. We fly as one and invite others to join us. We`re headquartered in Cambridge, MA with additional nests in Seattle, WA, Durham, NC, and Zug, Switzerland.
Aspect DV is a Merrimack, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.
Tonix Pharmaceuticals develops first-in-class medicines for common disorders of the central nervous system, including fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache. These disorders are characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and significant economic burden. Tonix`s lead product candidate, TNX-102 SLAttribution (cyclobenzaprine HCl sublingual tablet), is designed to be a fundamental advance in sleep hygiene and pain management for patients suffering from fibromyalgia and post-traumatic stress disorder (PTSD). Product candidate TNX-201Attribution ((R)-isometheptene mucate) is in development for episodic tension-type headache, the most common form of headache.
Advance Nanotech Inc is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.